A Phase 1 interventional study of [64Cu]FBP8 and PET/MR in Atrial Fibrillation, COVID-19 and Cancer, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Massachusetts General Hospital · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Atrial Fibrillation by Massachusetts General Hospital — 4 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Massachusetts General Hospital.
Among the 15 studies in Atrial Fibrillation by Massachusetts General Hospital, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is the only one in phase 1, and was the 9th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →4 of the 15 studies in Atrial Fibrillation by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–80
Massachusetts General Hospital · Sites in United States
Ages 18–90 · Healthy volunteers
Massachusetts General Hospital
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1985; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is close to the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 165 across the 13 interventional studies, 242 across the 1 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
1 of the studies in Atrial Fibrillation by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03830320Massachusetts General HospitalPositron Emission Tomography (PET) Imaging of Thrombosis | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Atrial Fibrillation by Massachusetts General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.
The primary objectives of this study are:
For Atrial Fibrillation Patient subjects:
For COVID-19 Patient subjects:
For Cancer Patient subjects:
For Other Patient subjects:
Exclusion criteria: A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Additional exclusion criteria for Atrial Fibrillation Patient subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twenty (20) healthy adult subjects will be injected with \[64Cu\]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
Drug: [64Cu]FBP8 · Device: PET/MR · Procedure: Blood Collection · Procedure: Electrocardiogram
Thirty-five (35) patients with LAA thrombus documented by TEE will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care. Thirty-five (35) patients with atrial fibrillation and negative TEE will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus. Forty (40) patients with atrial fibrillation who are scheduled for TEE in the upcoming 14 days will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus.
Drug: [64Cu]FBP8 · Device: PET/MR
Thirty (30) COVID-19 patients will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.
Drug: [64Cu]FBP8 · Device: PET/MR
Thirty (30) cancer patients will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.
Drug: [64Cu]FBP8 · Device: PET/MR
Fifty (50) patients with other thrombotic conditions will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.
Drug: [64Cu]FBP8 · Device: PET/MR
Injection of Copper-64 radiopeptide to detect thrombosis
Also known as: 64Cu-FBP8
Whole body imaging using Siemens mMR PET/MR scanner
Also known as: PET-MR
A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
Also known as: ECG
Complete blood count
To model pharmacokinetics of \[64Cu\]FBP8 metabolism in healthy volunteers.
Time frame: 36 hours
Target to Background Ratio LAA
To determine the signal threshold of \[64Cu\]FBP8 that produces the highest accuracy of \[64Cu\]FBP8 -PET to detect left atrial thrombosis in patients with atrial fibrillation.
Time frame: 4 hours
Target to Background Ratio
To determine the signal threshold of \[64Cu\]FBP8 that produces the highest accuracy of \[64Cu\]FBP8 -PET to detect thrombosis in patients with known thrombus or suspicion of thrombus.
Time frame: 4 hours
Time activity curve
To evaluate human dosimetry and radiation burden in healthy volunteers.
Time frame: 48 hours
Started Apr 2016 (actual). Primary completion is estimated for Jan 2027, 129 months after the start.
Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 129 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Copper Cu 64 FBP8
Massachusetts General Hospital →